- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07664319
Effect of Platelet-Rich Plasma on Eardrum Healing and Hearing After Tympanoplasty in Adults
Intraoperative Use of Platelet-Rich Plasma in Tympanoplasty: Effects on Graft Success and Audiological Outcomes - A Prospective Controlled Trial
Visão geral do estudo
Status
Descrição detalhada
Study design and ethics This prospective, single-center, randomized controlled trial was conducted at the Otolaryngology-Head and Neck Surgery Clinic of Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, between April 1 and June 30, 2023. The protocol received ethics committee approval (decision no. 3857, April 4, 2023). All participants provided written informed consent before enrolment. The trial was conducted in accordance with the Declaration of Helsinki.
Participants Adults aged 18-65 years were eligible if they had a central tympanic membrane perforation present for at least six months without active discharge in the preceding three months, were able to undergo and cooperate with preoperative pure-tone audiometry, and were available for follow-up. Exclusion criteria were: planned concurrent mastoidectomy, cholesteatoma on preoperative imaging or intraoperative inspection, a history of ventilation tube insertion on the affected side, revision surgery, uncontrolled hypertension or diabetes mellitus, coagulation disorder or antiplatelet/anticoagulant therapy, anaemia (Hgb <12 g/dL) or thrombocytopaenia (platelets <150,000/μL), active malignancy, and serious psychiatric illness.
Randomization Patients who met inclusion criteria were allocated by simple alternation: the first eligible patient was assigned to the PRP group, the second to the control group, the third to the PRP group, and so on. Patients were not informed of their group assignment (single-blind design). Surgeons were necessarily aware of group allocation.
Sample size Sample size was calculated with G*Power version 3.1.6. Based on an expected large effect size (Cohen's d = 0.62) derived from comparable prospective cohort data, a two-sided α of 0.05, and a power of 80%, the required sample was 48 patients (24 per group).
PRP preparation PRP was prepared manually at the start of each operation in the PRP group. After intravenous access was established, 8.5 mL of venous blood was drawn into a glass tube containing 1.5 mL of acid citrate dextrose (ACD-A solution; Becton Dickinson, Plymouth, UK) using an 18-gauge needle. The tube was centrifuged at 419 × g (2,500 rpm) for 8 minutes in a Tomos Centrifuge 802B (Tomos Life Science Group, Shanghai, China), balanced against a tube of equal weight containing normal saline. The platelet-rich buffy coat layer and the overlying plasma were carefully aspirated using a spinal cannula into a sterile, anticoagulant- free 10-mL tube. This tube was then centrifuged at 822 × g (3,500 rpm) for 8 minutes. The upper two-thirds of the supernatant were discarded, and the remaining platelet concentrate was gently resuspended by inverting the tube several times. This final product was used to saturate the spongostans immediately before placement.
Surgical technique The surgeries were performed under general anesthesia by one of six experienced ENT specialists. The approach (transcanal, endoauricular, or retroauricular) was determined preoperatively based on the location and size of the perforation, the anatomy of the external auditory canal, and the surgeon's preference. After standard preparation and local infiltration with 20 mg/mL lidocaine plus 0.0125 mg/mL epinephrine, the perforation edges were de- epithelialized with an instrument. The ossicular chain was examined and reconstructed as needed. In the PRP group, PRP-impregnated spongy bone was placed in the middle ear cavity and next to the graft. In the control group, dry spongy bone was placed in the same positions. The graft material (cartilage, temporal fascia, or fat) was selected according to the perforation characteristics and the surgeon's preference. An under- or over-under placement technique was used as needed. The external auditory canal was filled with antibiotic-impregnated gauze strips (bacitracin 500 IU/g + neomycin 5 mg/g ointment). All patients received 0.3% ciprofloxacin ear drops three times a day for one week after surgery.
Outcome measures and follow-up Patients were reviewed at two weeks (suture removal and packing removal) and at two months. At the two-month visit, the tympanic membrane was examined under microscopy and graft integrity was recorded (binary outcome: intact or perforated). Pure-tone audiometry was performed in a sound-treated booth using an Interacoustics AC 40 audiometer in accordance with ISO standards and American Speech-Language-Hearing Association criteria. Thresholds were measured at 250, 500, 1000, 2000, and 4000 Hz by air and bone conduction. The ABG was calculated as the mean air-bone gap across 500, 1000, 2000, and 4000 Hz. Hearing gain was defined as the difference between preoperative and postoperative ABG. Perforation area was measured intraoperatively using a calibrated 2-mm Rosen elevator and diamond burrs of known diameter; it was recorded for descriptive purposes only and was not a selection criterion.
Statistical analysis Analyses were performed with SPSS 15.0 for Windows. Categorical variables were compared with Chi-square tests; continuous variables were compared with independent- samples t-tests when normally distributed (Shapiro-Wilk test, p>0.05) or Mann-Whitney U tests otherwise. Within-group pre- to postoperative changes were assessed with paired t-tests or Wilcoxon signed-rank tests as appropriate. Bonferroni correction was applied for multiple comparisons. Statistical significance was defined as p<0.05 (two-tailed).
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Sisli
-
Istanbul, Sisli, Turquia (Türkiye), 34700
- Sbü Sisli Hamidiye Etfal Eah
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Central tympanic membrane perforation present for at least 6 months No active discharge in the preceding 3 months Able to undergo and cooperate with preoperative pure-tone audiometry Available for follow-up
Exclusion Criteria:
- Planned concurrent mastoidectomy Cholesteatoma (on imaging or intraoperative inspection) History of ventilation tube insertion on the affected side Revision surgery Uncontrolled hypertension or diabetes mellitus Coagulation disorder or antiplatelet/anticoagulant therapy Anaemia (Hgb <12 g/dL) or thrombocytopenia (platelets <150,000/µL) Active malignancy Serious psychiatric illness Occupation involving high pressure changes (e.g., diver, pilot) Rheumatic disease history
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1 - PRP group
Autologous PRP-impregnated Spongostan placed in the middle ear and lateral to the graft during tympanoplasty.
|
PRP-impregnated absorbable gelatin sponge placed in the middle ear and lateral to the graft during tympanoplasty
|
|
Comparador Ativo: Arm 2 - Control group
Dry Spongostan placed in the same positions, without PRP.
|
Dry absorbable gelatin sponge placed in the same positions without PRP
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Graft integrity (intact tympanic membrane)
Prazo: 2 months postoperatively
|
Proportion of patients with an intact tympanic membrane (no residual perforation) on otomicroscopic examination.
|
2 months postoperatively
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Air-bone gap (ABG)
Prazo: 2 months postoperatively
|
Mean air-bone gap on pure-tone audiometry, averaged across 500, 1000, 2000, and 4000 Hz.
|
2 months postoperatively
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hearing gain
Prazo: 2 months postoperatively
|
Difference between preoperative and postoperative air-bone gap.
|
2 months postoperatively
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Ethics committee number: 3857
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .